Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
3.210
+0.020 (0.63%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Niagen Bioscience Employees
Niagen Bioscience had 117 employees as of December 31, 2025. The number of employees increased by 13 or 12.50% compared to the previous year.
Employees
117
Change (1Y)
13
Growth (1Y)
12.50%
Revenue / Employee
$1,114,667
Profits / Employee
$159,291
Market Cap
256.19M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 117 | 13 | 12.50% | 117 | 0 |
| Dec 31, 2024 | 104 | -2 | -1.89% | 104 | 0 |
| Dec 31, 2023 | 106 | -7 | -6.19% | 106 | 0 |
| Dec 31, 2022 | 113 | -2 | -1.74% | 113 | 0 |
| Dec 31, 2021 | 115 | 5 | 4.55% | 115 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 2, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Lineage Cell Therapeutics | 77 |
| InflaRx | 65 |
| Fulcrum Therapeutics | 55 |
| Surrozen | 44 |
| ALX Oncology Holdings | 43 |
| Sol-Gel Technologies | 28 |
| Opus Genetics | 28 |
NAGE News
- 4 days ago - Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Business Wire
- 4 days ago - Niagen Bioscience price target lowered to $11 from $12 at Ladenburg - TheFly
- 9 days ago - Niagen Bioscience appoints Kale as Senior Director of Global External Research - TheFly
- 9 days ago - Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research - Business Wire
- 10 days ago - Niagen Bioscience Transcript: Fireside chat - Transcripts
- 10 days ago - Niagen Bioscience Slides: Corporate presentation - Filings
- 12 days ago - Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168 - TheFly
- 12 days ago - Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) - Business Wire